Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin
Released On: 05/03/2021
Views: 709
Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC
Released On: 03/03/2021
Views: 684
Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin
Released On: 01/03/2021
Views: 728
AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
Released On: 01/03/2021
Views: 1102
Meet Aikido Pharma Inc’s Board of Directors
Released On: 28/02/2021
Views: 729
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
Released On: 23/02/2021
Views: 770
Artificial Intelligence Is Optimizing Drug Development
Released On: 22/02/2021
Views: 777
Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer
Released On: 20/02/2021
Views: 663
AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock
Released On: 19/02/2021
Views: 827
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
Released On: 16/02/2021
Views: 926
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
Released On: 16/02/2021
Views: 878
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
Released On: 16/02/2021
Views: 965
Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine
Released On: 15/02/2021
Views: 677
Aikido Pharma Establishes Licensing Agreement with University of Maryland for Antiviral Compounds, Including COVID-19
Released On: 10/02/2021
Views: 591
Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.
Released On: 09/02/2021
Views: 1135
Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer
Released On: 05/02/2021
Views: 731
AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board
Released On: 03/02/2021
Views: 1587
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
Released On: 03/02/2021
Views: 802
Map
Aikido Pharma
Get DirectionsAikido Pharma
-
One Rockefeller Plaza
New York, New York 10020
United States - (212) 745-1373
